Abstract
Biopharmaceuticals are definitely different from chemical drugs. This is not a perception, but a reality, and it is reflected by the statements on regulatory authority websites and in the wording of the regulatory guidances that they issue. Also, as is shown in this chapter, the four major CMC differences between biopharmaceuticals and chemical drugs are discussed: (1) how the products are synthesized, (2) impact of the process on the manufactured product, (3) complexity of the manufactured product, and (4) biosimilars are not bio-generics.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
FDA About the Center for Biologics Evaluation and Research: What Are “Biologics – Questions and Answers; FDA website, www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077.htm
FDA Drugs: Frequently Asked Questions About Therapeutic Biological Products; FDA website, www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.htm
EMA Biosimilars in the EU: Information Guide for Healthcare Workers (April 2017); www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
EU EudraLex The Rules Governing Medicinal Products in the European Union, Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 2 Manufacture of Biological Medicinal Substances and Products for Human Use (June 2018); ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/pdfs-en/2018_annex2_en.pdf
ICH Q6A Specifications: Test Procedures and Acceptance Criteria For New Drug Substances and New Drug Products: Chemical Substances (October 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6A/Step4/Q6Astep4.pdf
ICH Q6B Specifications: Test Procedures and Acceptance Criteria For Biotechnological/Biological Products (March 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
ICH Q1A(R2) Stability Testing of New Drug Substances and New Drug Products (February 2003); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf
ICH Q5C Stability Testing of Biotechnological/Biological Products (November 1995); ICH website, www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5C/Step4/Q5C_Guideline.pdf
ICH Q5A(R1) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin (September 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5A_R1/Step4/Q5A_R1__Guideline.pdf
FDA Generic Drugs: What is the Approval Process for Generic Drugs; FDA website, www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/GenericDrugs/ucm506040.htm
FDA CPG Sec. 420.100 Adulteration of Drugs Under Section 501(b) and 501(c) of the Act (May 1992); www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-ice/documents/webcontent/ucm074367.pdf
Council of Europe: European Pharmacopeia (Ph.Eur.) – Background & Mission; EDQM website, www.edqm.eu/en/european-pharmacopoeia-background-50.html
FDA Letter to USP: Drug Product Monographs for Biological Products (March 28, 2018); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM602973.pdf
ICH Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process (November 2004); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf
FDA Biotechnology Inspection Guide (November 1991); www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074181.htm
Schiestl, M., Stangler, T., et al., Acceptable Changes in Quality Attributes of Glycosylated Biopharmaceuticals; Nat Biotechol (2011) 29: 310–312
FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product (April 2015); www.fda.gov/downloads/drugs/guidances/ucm291134.pdf
Deller, M.C., Kong, L, and Rupp B., Protein Stability: A Crystallographer’s Perspective; Acta Cryst. (2016) F72: 72–95; www.ncbi.nlm.nih.gov/pmc/articles/PMC4741188/
FDA Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications (February 2010); www.fda.gov/downloads/BiologicsBloodVaccines/UCM202439.pdf
FDA Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products (June 2015); www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM564952.pdf
FDA Vaccines, Blood & Biologics: Biologics Research Projects – Evaluation of Safety and Potency of Viral Vaccines Based on Analysis of Molecular Consistency; FDA website, www.fda.gov/BiologicsBloodVaccines/ScienceResearch/BiologicsResearchAreas/ucm127312.htm
EMA Guideline on the Quality, Non-Clinical and Clinical Aspects of Gene Therapy Medicinal Products (March 2018); www.ema.europa.eu/documents/scientific-guideline/guideline-quality-non-clinical-clinical-aspects-gene-therapy-medicinal-products_en.pdf
EMA/EC: Biosimilars in th EU – Information Guide for Healthcare Professionals (2017); www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
Kozlowski, S. and Swann, P., Current and Future Issues in the Manufacturing and Development of Monoclonal Antibodies; Adv. Drug Deliv Rev. (2006 Aug 7) 58 (5–6): 707–722
EMA Guideline on Immunogenicity Assessment of Therapeutic Proteins (May 2017); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/06/WC500228861.pdf
EMA European Public Assessment Report (EPAR): Glybera (Alipogene Tiparvovec) (July 2012); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002145/WC500135476.pdf
FDA – Speeches by FDA Officials: Remarks by Commissioner Gottlieb to the Alliance for Regenerative Medicine’s Annual Board Meeting (May 22, 2018); www.fda.gov/NewsEvents/Speeches/ucm609579.htm
FDA Drugs – Therapeutic Biological Applications (BLA): Biosimilars – Biosimilar and Interchangeable Products; FDA website, www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm
EMA/EC What I Need to Know About Biosimilar Meedicines – Information for Patients (2017); ec.europa.eu/growth/content/information-patients-what-i-need-know-about-biosimilar-medicines-0_en
Health Canada Biologics, Radiopharmaceuticals and Generic Therapies: Fact Sheet - Biosimilars; HC website, www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html
World Health Organization Biologicals – Similar Biotherapeutic Products: Annex 2 – Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) – Technical Report Series No. 977 (2013); www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1
FDA Drugs – Therapeutic Biological Applications (BLA): Biosimilars – Biosimilar Development, Review and Approval; FDA website, www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580429.htm
FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product (April 2015); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf
EMA Procedural Advice for Users of the Centralised Procedure for Similar Biological Medicinal Products Applications (May 2017); www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125166.pdf
World Health Organization Expert Committee on Biological Standardization: Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) (2009); www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
FDA Drugs -Therapeutic Biologic Applications (BLA): Biosimilar and Interchangeable Products; FDA website, www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm#biosimilar
EMA/EC Biosimilars in the EU: Information guide for healthcare professionals (2017); www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
FDA Draft Guidance for Industry: Considerations in Demonstrating Interchangeability with a Reference Product (January 2017); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf
WHO Essential Medicines and Health Products: International Nonproprietary Names; WHO website, www.who.int/medicines/services/inn/en/
FDA Guidance for Industry: Nonproprietary Naming of Biological Products (January 2017); www.fda.gov/downloads/drugs/guidances/ucm459987.pdf
WHO Essential Medicines and Health Products: Biological Qualifier; WHO website, www.who.int/medicines/services/inn/inn_bio_bq/en/
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Geigert, J. (2019). Biopharmaceuticals Are Not Chemical Drugs. In: The Challenge of CMC Regulatory Compliance for Biopharmaceuticals . Springer, Cham. https://doi.org/10.1007/978-3-030-13754-0_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-13754-0_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13753-3
Online ISBN: 978-3-030-13754-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)